Tirzepatide (Mounjaro, Zepbound) Strengths: Highest efficacy for both glucose control and weight loss Dual mechanism (GLP-1 + GIP) may provide unique benefits Once-weekly dosing Generally well-tolerated Considerations: Higher cost than semaglutide Less long-term safety data (newer medication) Cardiovascular outcome trial not yet complete (though expected to be positive) Best for: Patients prioritizing maximum weight loss
When a routine runs that long, people need more than instructions
Certificado de anlisis por lote Lotes de Retatrutida con certificado de anlisis publicado en el catlogo de COA: Lote EXO010626027A 30 mg, emitido 2026-05-21 Lote EXO010626027B 15 mg, emitido 2026-05-22 Lote EXO010626027C 5 mg, emitido 2026-05-25 Lote EXO010626027D 10 mg, emitido 2026-05-22 Lote EXO010626027E 40 mg, emitido 2026-05-21 Lote EXO010626027F 50 mg, emitido 2026-05-23 Lote EXO010626027G 60 mg, emitido 2026-05-19 Lote EXO010626027H 20 mg, emitido 2026-05-27 Lote EXO010626027J 100 mg, emitido 2026-05-22 Referencias cientficas (4) Literatura revisada por pares sobre Retatrutida, con su identificador PubMed cuando est disponible: Retatrutide en MASLD Estudio fase 2 (Sanyal AJ, Kaplan LM, Frias JP, et al
Drawing a 7.5mg dose At 5mg/ml (2ml water added): You need 150 units